Education
About Us
Working with TipRanks
Follow Us
Cencora (DE:ABG)
BERLIN:ABG
ABG Stock Chart & Stats
Day’s Range― - ―
52-Week Range€197.10 - €271.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$49.84B
Enterprise Value€59.80B
Total Cash (Recent Filing)$3.22B
Total Debt (Recent Filing)$8.15B
Price to Earnings (P/E)31.3
Beta-0.15
Next Earnings
Jul 30, 2025EPS Estimate
3.41Last Dividend Ex-Date
May 16, 2025Dividend Yield0.73%
Share Statistics
EPS (TTM)3.95
Shares Outstanding193,823,490
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-6.08
Price to Book (P/B)242.01
Price to Sales (P/S)0.00
P/FCF Ratio-86.00
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue0.05
Enterprise Value/Gross Profit6.36
Enterprise Value/Ebitda4.30
Forecast
1Y Price Target
$287.12Price Target Upside13.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Cencora News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company's adjusted EPS beat estimates, showcasing strong financial performance.
Growth StrategyCencora, Inc.'s acquisition strategies, including those of RCA and OneOncology, have enhanced its Specialty income streams, providing opportunities for further expansion.
Market PositionThe focus on winning in the Specialty Rx market and deepening relationships with specialty providers aligns with a strong strategy for COR.
Bears Say
Customer RelationsThere is uncertainty around the relationship with WBA, which is COR’s largest customer, as recent commentary sounded somewhat adversarial.
International PerformanceThe international segment of Cencora, Inc. showed disappointing performance, with an expected guide down due to slow clinical trial activity.
Valuation ConcernsValuation feels relatively full compared to significant discounts across much of the rest of the coverage universe.
Options Prices
Currently, No data available
---
Ownership Overview
6.82% Insiders
26.68%
Mutual Funds
0.79% Other Institutional Investors
42.05% Public Companies and Individual Investors
ABG FAQ
What was Cencora’s price range in the past 12 months?
Cencora lowest stock price was €197.10 and its highest was €271.40 in the past 12 months.
What is Cencora’s market cap?
Cencora’s market cap is $49.84B.
When is Cencora’s upcoming earnings report date?
Cencora’s upcoming earnings report date is Jul 30, 2025 which is in 67 days.
How were Cencora’s earnings last quarter?
Cencora released its earnings results on May 07, 2025. The company reported €3.946 earnings per share for the quarter, beating the consensus estimate of €3.673 by €0.272.
Is Cencora overvalued?
According to Wall Street analysts Cencora’s price is currently Undervalued.
Does Cencora pay dividends?
Cencora pays a Quarterly dividend of €1.899 which represents an annual dividend yield of 0.73%. See more information on Cencora dividends here
What is Cencora’s EPS estimate?
Cencora’s EPS estimate is 3.41.
How many shares outstanding does Cencora have?
Cencora has 193,823,490 shares outstanding.
What happened to Cencora’s price movement after its last earnings report?
Cencora reported an EPS of €3.946 in its last earnings report, beating expectations of €3.673. Following the earnings report the stock price went down -0.059%.
Which hedge fund is a major shareholder of Cencora?
Currently, no hedge funds are holding shares in DE:ABG
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$287.12 (13.26% Upside)
$287.12 (13.26% Upside)
Blogger Sentiment
Bullish
DE:ABG Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $2.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.14%
12-Months-Change
Fundamentals
Return on Equity
161.58%
Trailing 12-Months
Asset Growth
11.47%
Trailing 12-Months
Company Description
Cencora
Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
ABG Company Deck
ABG Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Cencora showcased strong financial performance with significant revenue and EPS growth, and raised guidance due to the success of its U.S. Healthcare Solutions segment and effective cost management. However, challenges in the international segment and increased interest expenses slightly offset these positive outcomes.Read More>ABG Revenue Breakdown
89.54% U.S. Healthcare Solutions
10.46% International Healthcare Solutions
ABG Stock 12 Month Forecast
Average Price Target
€287.12
▲( 13.26% Upside)